Table 1.
AR (+) | AR (−) | P‐value | |
---|---|---|---|
(n = 16) | (n = 30) | ||
Gender | |||
Male/female | 13/3 | 20/10 | 0.295 |
Age | |||
Median | 67 | 65.5 | 0.133 |
Range | 56–85 | 36–80 | |
PS | |||
0 | 9 | 17 | |
1 | 5 | 11 | 0.780 |
2 | 2 | 2 | |
Extent of disease | |||
Local advance | 0 | 3 | 0.191 |
Metastasis | 16 | 27 | |
The number of metastatic organ | |||
0 | 0 | 3 | |
1 | 4 | 15 | 0.119 |
2 | 9 | 8 | |
≥3 | 3 | 4 | |
Histological type | |||
Intestinal type | 2 | 6 | 0.523 |
Diffuse type | 14 | 24 | |
First line chemotherapy | |||
S1 | 9 | 11 | |
S1+CDDP | 2 | 8 | 0.373 |
S1+PTX | 5 | 11 |
CDDP, cisplatin; PTX, paclitaxel; PS, performance status; S1, oral tegafur, 5‐chloro‐2,4‐dihydropyrimidine and potassium oxonate.